Clinical Trials Logo

Advanced Melanoma clinical trials

View clinical trials related to Advanced Melanoma.

Filter by:

NCT ID: NCT03917069 Recruiting - Advanced Melanoma Clinical Trials

Nab-PCE vs PC for MM After Failure of Anti-PD-1

Start date: March 23, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin - Endostatin for advanced melanoma after failure of PD-1 therapy. The aim was to evaluate the efficacy and safety of nab-paclitaxel+carboplatin - endostatin versus combination of paclitaxel and carboplatin in patients with advanced melanoma after failure of PD-1 therapy.

NCT ID: NCT03818893 Recruiting - Advanced Melanoma Clinical Trials

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Start date: March 2019
Phase: Phase 2
Study type: Interventional

This is a multi-center, open-labeled, non-randomized, single arm investigator-initiated trial to evaluate the safety and efficacy of GEN0101 and Pembrolizmub combination in patients with advanced melanoma.

NCT ID: NCT03815058 Active, not recruiting - Advanced Melanoma Clinical Trials

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

IMCODE001
Start date: January 8, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

NCT ID: NCT03776136 Completed - Advanced Melanoma Clinical Trials

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Start date: January 30, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of combination therapy of lenvatinib (E7080/MK-7902) and pembrolizumab following approximately 2 years of pembrolizumab therapy and approximately 2 years or more lenvatinib therapy in adult participants with unresectable or advanced melanoma who have been exposed to anti-PD-1/L1 agents approved for unresectable or metastatic melanoma. No statistical hypothesis will be tested in this study.

NCT ID: NCT03724968 Terminated - Metastatic Melanoma Clinical Trials

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

Start date: January 17, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, non-randomized two arm Phase 2 study of intravenous nivolumab plus intravenous ipilimumab or intravenous relatlimab in patients with metastatic melanoma stratified by MHC-II expression.

NCT ID: NCT03707574 Active, not recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Start date: April 9, 2019
Phase:
Study type: Observational

This trial studies the genetic analysis of blood and tissue samples from patients with cancer that has spread to other anatomic sites (advanced) or is no longer responding to treatment. Studying these samples in the laboratory may help doctors to learn how genes affect cancer and how they affect a person's response to treatment.

NCT ID: NCT03502330 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Start date: June 9, 2018
Phase: Phase 1
Study type: Interventional

This trial is a phase 1/1b study to evaluate the safety, efficacy, and tolerability of APX005M in combination with nivolumab and cabiralizumab. The phase 1 dose escalation portion of the study will enroll patients with advanced solid tumors melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) in 6 cohorts to determine the recommended phase II dose (RP2D) of APX005M. The phase 1b dose expansion portion will study the triple drug combination separately in the three disease cohorts: melanoma, NSCLC, and RCC.

NCT ID: NCT03501368 Active, not recruiting - Melanoma Clinical Trials

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Start date: June 27, 2018
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA) given in combination with trametinib (MEKINIST) in patients who have progressed on prior melanoma therapy.

NCT ID: NCT03422445 Recruiting - Advanced Melanoma Clinical Trials

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Start date: January 8, 2018
Phase: Phase 2
Study type: Interventional

30 patients with advanced melanoma will receive apatinib plus Temozolomide as maintenance therapy.

NCT ID: NCT03407170 Terminated - Advanced Melanoma Clinical Trials

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Start date: June 28, 2018
Phase: Phase 2
Study type: Interventional

In this study, participants with advanced melanoma will be treated with pembrolizumab (MK-3475) and their tumors and blood will be analyzed for changes related to pembrolizumab therapy. The primary hypotheses are that participants who respond to pembrolizumab have: 1. a higher fraction of cytotoxic tumor-infiltrating T-lymphocytes (FCT) at baseline compared to those who do not respond to pembrolizumab 2. a higher fold-increase in FCT compared to baseline than those who do not respond to pembrolizumab 3. a higher Average Specific Cytotoxic T-lymphocyte Frequency Ratio (ASCTFR) compared to those who do not respond to pembrolizumab